Estimating the dynamic early life exposure to PFOA and PFOS of the HELIX children: Emerging profiles via prenatal exposure, breastfeeding, and diet.

Children Human biomonitoring In utero Longitudinal cohorts PBPK model Reverse dosimetry

Journal

Environment international
ISSN: 1873-6750
Titre abrégé: Environ Int
Pays: Netherlands
ID NLM: 7807270

Informations de publication

Date de publication:
02 Apr 2024
Historique:
received: 26 10 2023
revised: 29 03 2024
accepted: 31 03 2024
medline: 10 4 2024
pubmed: 10 4 2024
entrez: 9 4 2024
Statut: aheadofprint

Résumé

In utero and children's exposure to per- and polyfluoroalkyl substances (PFAS) is a major concern in health risk assessment as early life exposures are suspected to induce adverse health effects. Our work aims to estimate children's exposure (from birth to 12 years old) to PFOA and PFOS, using a Physiologically-Based Pharmacokinetic (PBPK) modelling approach. A model for PFAS was updated to simulate the internal PFAS exposures during the in utero life and childhood, and including individual characteristics and exposure scenarios (e.g., duration of breastfeeding, weight at birth, etc.). Our approach was applied to the HELIX cohort, involving 1,239 mother-child pairs with measured PFOA and PFOS plasma concentrations at two sampling times: maternal and child plasma concentrations (6 to 12 y.o). Our model predicted an increase in plasma concentrations during fetal development and childhood until 2 y.o when the maximum concentrations were reached. Higher plasma concentrations of PFOA than PFOS were predicted until 2 y.o, and then PFOS concentrations gradually became higher than PFOA concentrations. From 2 to 8 y.o, mean concentrations decreased from 3.1 to 1.88 µg/L or ng/mL (PFOA) and from 4.77 to 3.56 µg/L (PFOS). The concentration-time profiles vary with the age and were mostly influenced by in utero exposure (on the first 4 months after birth), breastfeeding (from 5 months to 2 (PFOA) or 5 (PFOS) y.o of the children), and food intake (after 3 (PFOA) or 6 (PFOS) y.o of the children). Similar measured biomarker levels can correspond to large differences in the simulated internal exposures, highlighting the importance to investigate the children's exposure over the early life to improve exposure classification. Our approach demonstrates the possibility to simulate individual internal exposures using PBPK models when measured biomarkers are scarce, helping risk assessors in gaining insight into internal exposure during critical windows, such as early life.

Identifiants

pubmed: 38593693
pii: S0160-4120(24)00207-1
doi: 10.1016/j.envint.2024.108621
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108621

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Aude Ratier (A)

INERIS, Unit of Experimental Toxicology and Modelling, Verneuil-en-Halatte, France; PériTox Laboratory, UMR-I 01 INERIS, Université de Picardie Jules Verne, Amiens, France. Electronic address: aude.ratier@ineris.fr.

Maribel Casas (M)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiologa y Salud Pública (CIBERESP), Madrid, Spain.

Regina Grazuleviciene (R)

Department of Environmental Sciences, Vytautas Magnus University, Kaunas, Lithuania.

Remy Slama (R)

Team of Environmental Epidemiology, IAB, Institute for Advanced Biosciences, Inserm, CNRS, CHU-Grenoble-Alpes, University Grenoble-Alpes, CNRS, Grenoble, France.

Line Småstuen Haug (L)

Norwegian Institute of Public Health, Department of Food Safety, Oslo, Norway.

Cathrine Thomsen (C)

Norwegian Institute of Public Health, Department of Food Safety, Oslo, Norway.

Marina Vafeiadi (M)

Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.

John Wright (J)

Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.

Florence A Zeman (FA)

INERIS, Unit of Experimental Toxicology and Modelling, Verneuil-en-Halatte, France.

Martine Vrijheid (M)

ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiologa y Salud Pública (CIBERESP), Madrid, Spain.

Céline Brochot (C)

INERIS, Unit of Experimental Toxicology and Modelling, Verneuil-en-Halatte, France; Certara UK Ltd, Simcyp Division, Sheffield, UK.

Classifications MeSH